Lafunomyl

Alfuzosin, the active ingredient in Lafunomyl, is an alpha‑1 adrenergic antagonist presented as an oral tablet for the treatment of benign prostatic hyperplasia (BPH) in adult men. It relaxes smooth muscle in the prostate, bladder neck and urethra, improving urinary flow and reducing lower urinary tract symptoms.

GNH USA supplies Lafunomyl as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Alfuzosin is used to manage lower urinary tract symptoms associated with benign prostatic hyperplasia.

- Benign prostatic hyperplasia (BPH): improves urinary flow and reduces nocturia, urgency and weak stream. - Lower urinary tract symptoms (LUTS) due to BPH: alleviates frequency, hesitancy and incomplete emptying. - Acute urinary retention secondary to BPH: facilitates bladder emptying after catheter removal.

Alfuzosin may cause several adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness - Headache - Fatigue - Nasal congestion - Retrograde ejaculation - Gastrointestinal discomfort (nausea, abdominal pain)

Serious or Rare Side Effects: - Severe hypotension or syncope - Priapism - Allergic reactions such as rash or angioedema - Cardiac arrhythmia - Prolonged QT interval (rare) - Hepatic dysfunction (rare)

Before initiating therapy, clinicians should consider several safety aspects.

- Blood pressure monitoring: check baseline and periodically during treatment. - Hepatic impairment: dose adjustment may be required in moderate to severe liver disease. - Concomitant antihypertensives: assess risk of additive blood‑pressure lowering. - Avoid abrupt discontinuation: may cause rebound urinary symptoms. - Review all concurrent medications for potential alpha‑blocker interactions. - Store at ambient temperature: keep below 25 °C, protect from moisture and light.

Alfuzosin can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Other alpha‑blockers (e.g., tamsulosin, prazosin): risk of severe hypotension. - Potent CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase alfuzosin plasma levels. - Nitrates: additive vasodilatory effect leading to marked blood‑pressure drop. - Phosphodiesterase‑5 inhibitors combined with other alpha‑blockers: heightened risk of hypotension.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampin): may reduce alfuzosin efficacy. - Diuretics: monitor electrolytes and blood pressure. - Other antihypertensive agents: dose adjustments may be necessary.